Published in Ann Rheum Dis on March 01, 1971
Cytogenetic and scanning study of patients receiving intra-articular injections of gold-198 and yttrium-90. Ann Rheum Dis (1973) 1.93
Yttrium radiosynoviorthesis in the treatment of knee arthritis in rheumatoid arthritis: a systematic review. Ann Rheum Dis (2000) 1.06
The treatment of chronic knee joint synovitis with radioactive isotops (author's transl). Arch Orthop Unfallchir (1976) 0.85
Efficacy of radiosynovectomy in rheumatoid arthritis. Rheumatol Int (2011) 0.83
Effectiveness of radiation synovectomy with samarium-153 particulate hydroxyapatite in rheumatoid arthritis patients with knee synovitis: a controlled randomized double-blind trial. Clinics (Sao Paulo) (2009) 0.78
Can simple ultrasonography predict the clinical effect of intra-articular injection therapy of the knee joint? Clin Rheumatol (2010) 0.77
Irradiation treatment of rheumatoid arthritis. Br Med J (1973) 0.75
Effectiveness of radiation synovectomy with Yttrium-90 and Samarium-153 particulate hydroxyapatite in rheumatoid arthritis patients with knee synovitis: a controlled, randomized, double-blinded trial. Clin Rheumatol (2010) 0.75
EVALUATION OF INTRA-ARTICULAR COLLOIDAL GOLD AU 198 IN THE TREATMENT OF PRESISTENT KNEE EFFUSIONS. Ann Rheum Dis (1963) 3.12
Experiences of intra-articular administration of radioactive gold. Acta Rheumatol Scand (1967) 2.38
[Synoviorthesis with radioisotopes]. Presse Med (1968) 1.88
An investigation of radioactive yttrium (90Y) for the treatment of chronic knee effusions. Br J Radiol (1970) 1.83
Uptake of colloidal radioactive yttrium by synovial membrane. Ann Rheum Dis (1969) 1.59
Radioactive colloidal gold. In chronic knee effusions with Baker's cyst formation. Ann Rheum Dis (1970) 1.41
Radioactive colloidal gold in the treatment of chronic synovial effusions. Proc R Soc Med (1968) 1.05
Periarthritis of the shoulder and diabetes mellitus. Ann Rheum Dis (1972) 2.15
Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr (1978) 2.08
Studies of "potentially lethal damage" in EMT6 mouse tumour cells treated with bleomycin either in vitro or in vivo. Br J Cancer (1975) 2.02
Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) (1996) 1.93
Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour. Br J Cancer (1977) 1.90
The sensitivity to bleomycin of a solid mouse tumour at different stages of growth. Br J Cancer (1974) 1.88
p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene (1992) 1.84
An investigation of radioactive yttrium (90Y) for the treatment of chronic knee effusions. Br J Radiol (1970) 1.83
Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol (1997) 1.68
Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br J Cancer (1986) 1.66
Establishment and characterisation of cell lines from patients with lung cancer (predominantly small cell carcinoma). Br J Cancer (1985) 1.52
Hyperthermia in the treatment of cancer. Cancer Treat Rev (1979) 1.49
Final report of the general clinical results of the British Institute of Radiology fractionation study of 3F/wk versus 5F/wk in radiotherapy of carcinoma of the laryngo-pharynx. Br J Radiol (1990) 1.48
Higher cortisol content in hair among long-term unemployed individuals compared to controls. Psychoneuroendocrinology (2010) 1.45
The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised p02 histography. Br J Cancer (1992) 1.39
Irradiation of the synovium in the treatment of rheumatoid arthritis. Q J Med (1973) 1.35
Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer (1980) 1.33
Monitoring salivary misonidazole in man: a possible alternative to plasma monitoring. Br J Cancer (1978) 1.29
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party. Br J Cancer (1991) 1.26
The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer (1996) 1.20
An analysis of error in the retrieval of patient case note data. J Laryngol Otol (1970) 1.17
Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin [corrected]. Eur J Cancer (1991) 1.15
Drug resistance in human lung cancer cell lines: cross-resistance studies and effects of the calcium transport blocker, verapamil. Int J Radiat Oncol Biol Phys (1986) 1.15
Changes in cell proliferation kinetics occurring during the life history of monolayer cultures of a mouse tumour cell line. Cell Tissue Kinet (1975) 1.14
The sensitivity of cells in exponential and stationary phases of growth to bleomycin and to 1,3-bis(2-chloroethyl)-1-nitrosourea. Br J Cancer (1973) 1.13
The sensitivity to cytotoxic agents of the EMT6 tumor in vivo. Comparative response of lung nodules in rapid expotential growth and of the solid flank tumour. Br J Cancer (1976) 1.12
Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br J Cancer (1996) 1.12
Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia. Lancet (1972) 1.11
Clinical studies with misonidazole. Br J Cancer Suppl (1978) 1.10
An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer (1987) 1.10
Changes in sensitivity to cytotoxic agents occurring during the life history of monolayer cultures of a mouse tumour cell line. Br J Cancer (1975) 1.09
Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer (1989) 1.08
Erythematous oedema of the legs due to nifedipine. Br Med J (1978) 1.08
In vivo studies of radioactive phosphorus in malignant tumours. Clin Radiol (1967) 1.06
Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line. Br J Cancer (1977) 1.06
The sensitivity to bleomycin of spleen colony forming units in the mouse. Br J Cancer (1973) 1.04
Effect of cell density on intracellular adriamycin concentration and cytotoxicity in exponential and plateau phase EMT6 cells. Br J Cancer (1984) 1.01
Radiosensitivity testing of human malignant gliomas. Int J Radiat Oncol Biol Phys (1992) 0.99
Identification of Mycoplasma fermentans in synovial fluid samples from arthritis patients with inflammatory disease. J Clin Microbiol (2000) 0.98
Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res (1993) 0.96
The effect of bleomycin and radiation in combination on bacteria and mammalian cells in culture. Br J Radiol (1974) 0.96
Increased expression of human monocyte HLA-DR antigens and Fc gamma receptors in response to human interferon in vivo. Clin Exp Immunol (1983) 0.96
The prediction of invasive potential in superficial transitional cell carcinoma of the bladder. Br J Urol (1982) 0.96
Human blood group isoantigen expression on normal and malignant gastric epithelium studied with anti-A and anti-B monoclonal antibodies. J Natl Cancer Inst (1983) 0.95
Immunohistochemical techniques in the early screening of monoclonal antibodies to human colonic epithelium. Br J Cancer (1982) 0.94
An unusually proximal deletion on the short arm of chromosome 3 in a patient with small cell lung cancer. Genomics (1991) 0.93
Neuroendocrine differentiation and clinical behaviour in non-small cell lung tumours. Br J Cancer (1991) 0.92
Production of immunoreactive insulin-like growth factor-I (IGF-I) and IGF-I binding proteins by human lung tumours. Br J Cancer (1990) 0.92
Fifth progress report on the British Institute of Radiology fractionation trial of 3F-week or 5F-week treatment of larynx and pharynx. Br J Radiol (1972) 0.92
Sensitivity of normal mouse marrow and RIF-1 tumour to hyperthermia combined with cyclophosphamide or BCNU: a lack of therapeutic gain. Br J Cancer (1982) 0.91
Neurotensin in human small cell lung carcinoma. Br J Cancer (1984) 0.90
Pentoxifylline: its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. Radiother Oncol (1993) 0.90
Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) (1996) 0.90
Are blood group isoantigens lost from malignant prostatic epithelium? Immunohistochemical support for the preservation of the H isoantigen. Br J Cancer (1986) 0.90
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol (1996) 0.90
Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined. Br J Cancer (1995) 0.90
The response of a human tumour xenograft to chemotherapy: intrinsic variation between tumours and its significance in planning experiments. Br J Cancer Suppl (1980) 0.89
The Cambridge glioma trial of misonidazole and radiation therapy with associated pharmacokinetic studies. Cancer Clin Trials (1980) 0.89
Attempted targeting of a monoclonal antibody in a human tumour xenograft system. Eur J Cancer Clin Oncol (1981) 0.88
The treatment of inoperable lung cancer by radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys (1980) 0.88
Human lymphoblastoid interferon in the treatment of small cell lung cancer. Br J Cancer (1983) 0.88
Effects of two tumor blood flow modifiers, hydralazine and flavone acetic acid, on KHT tumours and normal tissues in mice. Int J Radiat Biol (1991) 0.88
The expression of ABH and Y blood group antigens in benign and malignant breast tissue: the preservation of the H and Y antigens in malignant epithelium. Br J Cancer (1986) 0.87
[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P induces apoptosis in lung cancer cell lines in vitro. Biochem Biophys Res Commun (1994) 0.87
The pharmacokinetics of misonidazole in the dog. Eur J Cancer (1979) 0.87
Measurements of resting energy expenditure and body composition before and after treatment of small cell lung cancer. Ann Oncol (1994) 0.87
Combination therapy with drugs and radiation. Br Med Bull (1973) 0.86
IGFBP-2: an important regulator of insulin-like growth factor action in human lung tumours? Growth Regul (1993) 0.86
Phase I and pharmacokinetic study of DACA (XR5000): a novel inhibitor of topoisomerase I and II. CRC Phase I/II Committee. Br J Cancer (1999) 0.86
The interaction of thermal tolerance with drug cytotoxicity in vitro. Br J Cancer (1979) 0.86
The in vitro effects and cross-resistance patterns of some novel anthracyclines. Br J Cancer (1986) 0.86
The hyperthermic potentiation of the cytotoxic effect of misonidazole on the EMT6 mouse tumour: relevance of in vitro measurement of in vivo effect. Br J Cancer Suppl (1978) 0.86
Neuron specific enolase expression in carcinoma of the lung. Br J Cancer (1986) 0.86
Radiotherapy for small cell lung cancer. Chest (1986) 0.85
The effects of alpha and gamma interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer (1985) 0.85
A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics. Br J Radiol (1986) 0.85
Thermochemotherapy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only. Br J Radiol (1985) 0.85
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. Br J Cancer (1995) 0.84
The penetration of misonidazole into spontaneous canine tumours. Br J Cancer (1979) 0.84
Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. Br J Cancer (1994) 0.84
A phase I study of the combination of benznidazole and CCNU in man. Int J Radiat Oncol Biol Phys (1984) 0.84
Insulin-like growth-factor-binding protein gene expression and protein production by human tumour cell lines. Int J Cancer (1992) 0.84
Primary lymphoma of the central nervous system: experience at Addenbrooke's Hospital, Cambridge. Clin Radiol (1988) 0.83
Small cell lung carcinoma. A phase II evaluation of r-interferon-gamma. Cancer (1987) 0.83
Monoclonal-antibody-defined human lung tumour cell-surface antigens. Int J Cancer (1985) 0.83
Oncogene amplification and chromosomal abnormalities in small cell lung cancer. J Cell Biochem (1987) 0.83
Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse. Br J Cancer (1980) 0.83
A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br J Cancer (1981) 0.83
Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro. Br J Cancer (1977) 0.82
A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer (1998) 0.82
Expression of insulinlike growth factor (IGF) and IGF-binding protein genes in human lung tumor cell lines. J Natl Cancer Inst (1992) 0.82
Role of radiation therapy in small cell anaplastic carcinoma of the lung. Cancer Treat Rep (1983) 0.82
Pentoxifylline increases RIF-1 tumour pO2 in a manner compatible with its ability to increase relative tumour perfusion. Acta Oncol (1995) 0.82
Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res (1991) 0.82
Early clinical experience with bleomycin in the United Kingdom in series of 105 patients. Br Med J (1972) 0.81